Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five ...

For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Blood centres cannot make cell therapies more accessible on their own. For decades they have partnered with hospitals to ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

Sensorion's gene therapy for otoferlin-related hearing loss – a congenital form of deafness – has shown early signs of improving hearing in two toddlers treated in a phase 1/2 trial.

Healthcare marketers looking for a fresh way to engage audiences across a wide range of demographics have turned to what may seem like an unusual source – sports. According to YouGov data, 67% ...

At its third attempt, Mesoblast has secured FDA approval for Ryoncil as a treatment for children with graft-versus-host disease, the first-ever approval for a mesenchymal stromal cell (MSC ...